Alkermes Says New Aripiprazole Is Just The Start Of A Blockbuster Streak
This article was originally published in The Pink Sheet Daily
Executive Summary
The CNS specialist outlined long-term commercial prospects for four drugs in its “emerging blockbuster” portfolio during an investor day presentation. The company also unveiled a new clinical candidate, a drug for the treatment of Alzheimer’s agitation.